Sarepta Therapeutics Inc's shares soared 64 percent after it said that the U.S. Food and Drug Administration indicated an alternate path to approval for the company's experimental muscle disorder drug.
http://ift.tt/1rdSu11
http://ift.tt/1rdSu11
Healthcare Law News: News on Healthcare Law continually updated from thousands of sources monitored by the B Media Network.
No comments:
Post a Comment